Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Barone, Paolo; Poewe, Werner; Albrecht, Stefan; Debieuvre, C.; Massey, Dan; Rascol, Olivier; Tolosa, Eduardo; Weintraub, Daniel

doi:10.1016/s1474-4422(10)70106-x

Cited by 488 publications

(295 citation statements)

References 35 publications

Supporting

Mentioning

264

Contrasting

Unclassified

Order By: Relevance

“…Consistent with this mechanism of action, pramipexole has a direct antidepressant effect in patients with PD (Leentjens et al, 2009) above and beyond its efficacy for motor symptoms associated with the illness (Barone et al, 2010). This antidepressant effect has also been noted in mood-disordered patients (Aiken, 2007), including patients with BPD (Goldberg et al, 2004;Zarate et al, 2004).…”

Section: Discussionmentioning

confidence: 86%

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Burdick

Braga

Gopin

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

We recently reported that the D2/D3 agonist pramipexole may have pro-cognitive effects in euthymic patients with bipolar disorder (BPD); however, the emergence of impulse-control disorders has been documented in Parkinson's disease (PD) after pramipexole treatment. Performance on reward-based tasks is altered in healthy subjects after a single dose of pramipexole, but its potential to induce abnormalities in BPD patients is unknown. We assessed reward-dependent decision making in euthymic BPD patients pre-and post 8 weeks of treatment with pramipexole or placebo by using the Iowa Gambling Task (IGT). The IGT requires subjects to choose among four card decks (two risky and two conservative) and is designed to promote learning to make advantageous (conservative) choices over time. Thirty-four BPD patients completed both assessments (18 placebo and 16 pramipexole). Baseline performance did not differ by treatment group (F ¼ 0.63; p ¼ 0.64); however, at week 8, BPD patients on pramipexole demonstrated a significantly greater tendency to make increasingly high-risk, high-reward choices across the five blocks, whereas the placebo group's pattern was similar to that reported in healthy individuals (treatment Â time Â block interaction, po0.05). Analyses of choice strategy using the expectancy valence model revealed that after 8 weeks on pramipexole, BPD patients attended more readily to feedback related to gains than to losses, which could explain the impaired learning. There were no significant changes in mood symptoms over the 8 weeks, and no increased propensity toward manic-like behaviors were reported. Our results suggest that the enhancement of dopaminergic activity influences risk-associated decision-making performance in euthymic BPD. The clinical implications remain unknown.

show abstract

Section: Discussionmentioning

confidence: 86%

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Burdick

Braga

Gopin

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…The evidence presented here focuses on the management of PD depression. Increases in dopaminergic medication dose, and particularly dopamine agonist doses, given the known efficacy of pramipexole in PD depression, may be considered as first-line treatment if the context is that of postoperative withdrawal of dopamine replacement therapy (Barone et al, 2010). However, if the depression is not that of a "specific" comorbid depression in PD with prominent apathy but absence of guilty thoughts and self-blame, and absence of suicidal behavior (Even and Weintraub, 2012), idiopathic depression may be more likely and the use of antidepressant treatment is indicated.…”

Section: Depressionmentioning

confidence: 99%

Psychiatric considerations in deep brain stimulation for Parkinson’s disease

Voon

Howell

Krack

2013

Handbook of Clinical Neurology

View full text Add to dashboard Cite

“…42 In a larger randomized-controlled study, the effectiveness of pramipexole for reducing depressive symptoms was validated. 43 Of course, a benefit of pramipexole is that it is used to treat motor symptoms as well, and this dual purpose could make it a very attractive agent. At the same time, it should be noted that pramipexole use has risks, including that it can cause dyskinesia.…”

Section: Dopamine Receptor Agonist Therapymentioning

confidence: 99%

The pharmacologic management of depression in Parkinson's disease

Schreiber¹,

Thompson²

2013

DNND

View full text Add to dashboard Cite

Depression in Parkinson's disease (PD) is common, and it appears to worsen the motor and cognitive progression of the disease, and limits the patient's quality of life. In this paper, we review the pharmacotherapy of depression in people with PD. We find that evidence is sparse when it comes to this patient population. There is some evidence that older tricyclic antidepressants (nortriptyline and desipramine) may be effective in this population. There is also growing evidence that newer antidepressants like paroxetine and venlafaxine may be effective. We will also review a number of other promising medication treatments. What is apparent is the need for more research identifying the most effective medications for treating depression in this population. We provide recommendations that fall in line with current evidence-based practice for managing depression in the general population. Also, we suggest that collaborative models of depression care may be a promising approach to support the identification and effective treatment of those with PD also suffering from depressive disorders.

show abstract

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Cited by 488 publications

References 35 publications

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Psychiatric considerations in deep brain stimulation for Parkinson’s disease

The pharmacologic management of depression in Parkinson's disease

Contact Info

Product

Resources

About

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Cited by 488 publications

References 35 publications

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients

Psychiatric considerations in deep brain stimulation for Parkinson’s disease

The pharmacologic management of depression in Parkinson&#39;s disease

Contact Info

Product

Resources

About

The pharmacologic management of depression in Parkinson's disease